AZ in ahead of Janssen, BMS

Posted 21 December 2020 PM

Astra Zeneca's $88,000-a-year lung cancer treatment Tagrisso has shot to the front of the PBS queue - overtaking two other major listings - with Health Minister Greg Hunt announcing it will be listed from January 1.

The treatment for non-small cell lung cancer for patients who have not had prior therapy was recommended by PBAC in July and pipped at least two other major listings from Janssen and Celgene (now BMS) in the race for a PBS berth.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here